-+ 0.00%
-+ 0.00%
-+ 0.00%

Moderna Publishes Presentation on Phase 3 Intismeran Melanoma Study

PUBT·10/24/2026 17:07:03
Moderna Publishes Presentation on Phase 3 Intismeran Melanoma Study
  • Moderna published an oncology presentation featuring Phase 3 INTerpath-001 results for individualized cancer therapy intismeran autogene.
  • The trial compares intismeran autogene with pembrolizumab against pembrolizumab alone as adjuvant treatment for resected stage IIB-IV melanoma.
  • The presentation reports a recurrence-free survival benefit maintained through five years of follow-up.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moderna Inc. published the original content used to generate this news brief on October 24, 2026, and is solely responsible for the information contained therein.